Posters
Effectiveness of intravitreal dexamethasone implants in the treatment of refractory postoperative macular oedema: a case report
Poster Details
First Author: P.Lutaj ALBANIA
Co Author(s): A. Lula
Abstract Details
Purpose:
To report that post-operative macular oedema is still a clinical problem, indicating that close observation of patients undergoing cataract surgery is required. Dexamethasone Implants might be an extremely effective option in the treatment of the refractory cases of this condition.
Setting:
University Hospital Centre ��Mother Theresa��, Department of Ophthalmology, Tirana, Albania
Methods:
This is a case report of a patient diagnosed with post-operative macular oedema in both eyes, treated with Dexamethasone intravitreal implants after failed first-line therapy (NSAID and Acetazolamide) and followed-up for 12 months. The diagnosis was based on visual acuity, clinical features of this condition, OCT and Fluoresceine Angiography (FFA) results.
Results:
The application of topical NSAID and Acetazolamide resulted in a minimal reduction of macular oedema. On the contrary, treatment with Dexamethasone intravitreal implants showed extremely effective results, reducing macular oedema (based on central retinal thickness CRT) to normal values within 45 days in both eyes (CRT was reduced from 763�Î�¼m to 187�Î�¼m in the right eye OD and from 751�Î�¼m to 165�Î�¼m in the left eye OS). Visual acuity returned to 6/6, 60 days after the Ozurdex injection.
Conclusions:
Dexamethasone intravitreal implants (Ozurdex) should be considered as an effective alternative for the treatment of post-operative macular oedema (Irvin-Gass Syndrome), especially in refractory cases with severe reduction in visual acuity and very high values of central retinal thickness (CRT). Close observation of these patients is required to reduce the risk of vision loss and prevent permanent damage of visual function due to changes in the multi-layer structure of the neuro-sensory retina and retinal pigment epithelium RPE caused by a large post-operative macular oedema.
Financial Disclosure:
NONE
